Covaxin, Bharat Biotech's COVID-19 Vaccine, Gets WHO Approval for Emergency Use Listing

Covaxin was found to have 78% efficacy against COVID19 of any severity, 14 or more days after the second dose. Moreover, the WHO statement also remarked that the Covaxin is extremely suitable for low- and middle-income countries due to easy storage requirements. 📰 Covaxin, Bharat Biotech's COVID-19 Vaccine, Gets WHO Approval for Emergency Use Listing.

Related Keywords

India ,Mexico ,Australia ,Estonia ,Iran ,Zimbabwe ,Nepal ,Paraguay ,Mauritius ,Guyana ,Greece ,Bharat ,Mansukh Mandviya ,Union Health ,Strategic Advisory Group Of Experts On Immunization ,Twitter ,World Health ,Indian Council Of Medical Research ,World Health Organisation ,Pfizer ,Bio Serum Institute Of India ,Bharat Biotech ,Hyderabad Based Bharat Biotech ,Indian Council ,Emergency Use Listing Approval From ,Serum Institute ,Approval Mean ,Sri Lanka ,Strategic Advisory Group ,Emergency Use Listing Nod From ,Approval Expands Availability ,Union Health Minister Mansukh Mandviya ,Coronavirus ,Covaxin ,Covid 19 Pandemic ,Covid 19 Vaccine Update ,Strategic Advisory Group Of Experts On Immunisation ,